In an effort to remove nearly $1 billion in annual costs, Johnson & Johnson (J&J; New Brunswick, N.J.) said it will cut about 3,000 or six percent of its medical device division workforce. The company announced the cost savings measure ahead of its earnings call slated for Jan. 26.
SAN FRANCISCO — Direct Flow Medical Inc. (Santa Rosa, Calif.), a private company known for its development of transcatheter aortic valve replacement (TAVR) solutions, is going back to its roots to develop a platform to address mitral valve disease. In an exclusive interview with Medical Device Daily, during the 34th annual J.P. Morgan Healthcare conference, Direct Flow Medical CEO, Dan Lemaitre, said the company would debut the valve during the Heart Team 2nd Mitral Valve Meeting 2016, running Feb. 14 through 16 in Zurich.
SAN FRANCISCO — Boston Scientific Corp.'s (Marlborough, Mass.) Synergy bioabsorbable polymer drug-eluting stent (DES) system and the Watchman left atrial appendage (LAA) closure device continue to be two pivotal products for the company going into 2016. The firm discussed the impact the technologies would have on it and discussed how transformational each product was going to be during the during a breakout session at the 34th annual J.P. Morgan Healthcare conference.
SAN FRANCISCO — Mergers and acquisitions will continue to be a big theme across the med-tech landscape, according to a report released at the 34th annual J.P. Morgan Healthcare conference. While 2015 produced the closing of one of the largest transactions in the med-tech space, via Medtronic plc's. (Dublin) acquisition of Covidien, J.P. Morgan analysts said there are more likely to be growth-enhancing deals than large-cap M&A or mergers of equals.
